PHARMACOLOGY & THERAPEUTICS

Executive Editors
W. C. Bowman, A. M. Breckenridge, A. C. Sartorelli.

CHEMOTHERAPY

CLINICAL PHARMACOLOGY & THERAPEUTICS

TOXICOLOGY

METABOLIC INHIBITORS

GENERAL & SYSTEMATIC PHARMACOLOGY

Volume contents, Author index
and Subject index to
Volume 24

PERGAMON PRESS OXFORD · NEW YORK

PHARMACOLOGY & THERAPEUTICS

Chemotherapy, Toxicology and Metabolic Inhibitors

Executive Editor: A. C. Sartorelli

Yale University School of Medicine, Department of Pharmacology, 333 *Cedar Street, New Haven, Connecticut* 06510, *USA*

Associate Editor: John S. Lazo

Managing Editor: Barbara Z. Renkin, Ph.D.

General and Systematic Pharmacology

Executive Editor: W. C. Bowman

University of Strathclyde, Department of Physiology & Pharmacology, Royal College, 204 *George Street, Glasgow G1 1XW, Scotland*

Clinical Pharmacology and Therapeutics

Executive Editor: A. M. Breckenridge

University of Liverpool, Department of Pharmacology & Therapeutics, P.O. Box 147, *Liverpool L69 3BX, England*

Editorial Board

G. E. Adams—*Sutton, Surrey, England*
S. Agoston—*Groningen, Netherlands*
Joseph R. Bertino—*New Haven, Connecticut*
Ernest Bueding—*Baltimore, Maryland*
B. A. Callingham—*Cambridge, England*
Donald S. Coffey—*Baltimore, Maryland*
William A. Creasey—*Philadelphia, Pennsylvania*
P. F. D'Arcy—*Belfast, N. Ireland*
M. A. Denborough—*Canberra, Australia*
Robert L. Dixon—*Research Triangle Park, North Carolina*
Jürgen Drews—*Wien, Austria*
W. F. Dryden—*Edmonton, Alberta, Canada*
B. L. Furman—*Glasgow, Scotland*
George A. Galegov—*Moscow, USSR*
C. F. George—*Southampton, England*
Evgeny Golovinsky—*Sofia, Bulgaria*
Robert E. Handschumacher—*New Haven, Connecticut*
Peter Langen—*Berlin, GDR*
Åke Liljestrand—*Stockholm, Sweden*
Jerry Mitchell—*Houston, Texas*
A. Nies—*Denver, Colorado*
E. E. Ohnhaus—*Essen, German Federal Republic*
M. L'E. Orme—*Liverpool, England*
J. Gy Papp—*Szeged, Hungary*
Robert E. Parks, Jr.—*Providence, Rhode Island*
Sidney Pestka—*Nutley, New Jersey*
William H. Prusoff—*New Haven, Connecticut*
J. L. Reid—*Glasgow, Scotland*
A. Richens—*Cardiff, Wales*
D. S. Savage—*Glasgow, Scotland*
D. G. Shand—*Durham, North Carolina*
David Shugar—*Warsaw, Poland*
F. Sjöqvist—*Huddinge, Sweden*
Jan Škoda—*Prague, Czechoslovakia*
A. Stafford—*Glasgow, Scotland*
Donald J. Tipper—*Worcester, Massachusetts*
E. S. Vesell—*Hershey, Pennsylvania*
George Weber—*Indianapolis, Indiana*
Gerhard Zbinden—*Zürich, Switzerland*

Library Annual Subscription Rates—published in 4 volumes per annum of 3 issues each.
Annual Subscription, 1985, U.S. $800.00 including postage and insurance, 2 years, 1985/86, U.S. $1520.00. *Specially Reduced Rates to Individuals*: Any individual whose institution takes out a library subscription may purchase a second or additional subscription for personal use at a much reduced rate of $350.00 annually. Subscribers to the Journal may claim a 20% discount off Encyclopedia volumes.

Subscription enquiries from customers in North America should be sent to Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523, USA, and for the remainder of the world to Pergamon Press Ltd, Headington Hill Hall, Oxford OX3 0BW, England.

At the end of the year, the Subscriber will receive, free, both the annual subject index and an attractive and durable magazine binder, especially designed for *Pharmacology & Therapeutics*.

Copyright © 1984 Pergamon Press Ltd.

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. However, assignment of copyright is not required from authors who work for organisations which do not permit such assignment. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproduction, microform or any other reproduction of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical photocopying recording or otherwise, without permission in writing from the copyright holder.

U.S. COPYRIGHT LAW APPLICABLE TO USERS IN THE U.S.A.

The Item-Fee Code for this publication indicates that authorization to photocopy items for internal or personal use is granted by the copyright holder for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance of $0.50 per page is paid directly to the Copyright Clearance Center Inc., 21 Congress Street, Salem, MA 01970. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific written permission must be obtained from the publisher for such copying. In case of doubt please contact your nearest Pergamon Office.

The Item-Fee Code for this publication is: 0163-7258/84 $0.00 + 0.50

Microform Subscriptions and Back Issues

Back issues of all previously published volumes are available in the regular editions and on microfilm and microfiche. Current subscriptions are available on microfiche simultaneously with the paper edition and on microfilm on completion of the annual index at the end of the subscription year.

Publishing and Advertising Offices

Pergamon Press Ltd.
Headington Hill Hall
Oxford OX3 0BW
England

Pergamon Press Inc.
Maxwell House
Fairview Park, Elmsford
New York 10523, U.S.A.

Volume 24, 1984, Numbers 1–3

CONTENTS

Number 1 PAGE

Behavioral effects of hypothalamic hypophysiotropic hormones, neurotensin, substance P and other neuropeptides: *C. B. Nemeroff, P. W. Kalivas, R. N. Golden and A. J. Prange, Jr* 1

Electrophysiological effects of peptides derived from pro-opiomelanocortin: *I. J. A. Urban* 57

Arachidonic acid metabolism, the endocrine pancreas, and diabetes mellitus: *R. P. Robertson* 91

5-Fluorouracil (FUra): *F. Valeriote and G. Santelli* 107

Mechanical properties of cellular cardiac preparations: *N. M. De Clerck and D. L. Brutsaert* 133

Number 2

Cell cycle effects of alkylating agents: *R. E. Meyn and D. Murray* 147

Possible value of H_2-receptor agonists for treatment of catecholamine-insensitive congestive heart failure: *G. Baumann, P. Permanetter and A. Wirtzfeld* 165

The pharmacology of drinking behavior: *L. M. Fuller* 179

Liposomes as drug carriers in cancer chemotherapy: *J. N. Weinstein and L. D. Leserman* 207

Biochemical pathways in interferon-action: *G. C. Sen* 235

Studies of the interferon receptors: *K. C. Zoon and H. Arnheiter* 259

A kinetic model of regulation of the deoxyribonucleoside triphosphate pool composition: *R. C. Jackson* 279

Number 3

Cellular and molecular effects of adriamycin on dividing and nondividing cells: *S. C. Barranco* 303

Action of proteolytic enzymes on lipotropins and endorphins: biosynthesis, biotransformation and fate: *J. P. H. Burbach* 321

Controlled delivery of drugs to the respiratory system: *R. L. Juliano* 355

Androgen antagonists in androgen target tissues: *D. J. Tindall, C. H. Chang, T. J. Lobl and G. R. Cunningham* 367

Methods of the detection and assessment of antiarrhythmic activity: *E. Winslow* 401

Age-related changes in the effects of drugs on the sweat glands: *K. Sato* 435

Inhibition of ribonucleotide reductase by α-(*N*)-heterocyclic carboxyaldehyde thiosemicarbazones: *E. C. Moore and A. C. Sartorelli* 439

AUTHOR INDEX

Arnheiter, H. 279

Barranco, S. C. 303
Baumann, G. 165
Brutsaert, D. L. 133
Burbach, J. P. H. 321

Chang, C. H. 367
Cunningham, G. R. 367

De Clerk, N. M. 133

Fuller, L. M. 179

Golden, R. N. 1

Jackson, R. C. 279
Juliano, R. L. 355

Kalivas, P. W. 1

Leserman, L. D. 207
Lobl, T. J. 367

Meyn, R. E. 147
Moore, E. C. 439
Murray, D. 147

Nemeroff, C. B. 1

Permanetter, B. 165
Prange, A. J., Jr 1

Robertson, R. P. 91

Santelli, G. 107
Sartorelli, A. C. 439
Sato, K. 435
Sen, G. C. 235

Tindall, D. J. 367

Urban, I. J. A. 57

Valeriote, F. 107

Weinstein, J. N. 207
Winslow, E. 401
Wirtzfeld, A. 165

Zoon, K. C. 259

SUBJECT INDEX

A21387 and insulin secretion 99
Adenylate cyclase assay 166, 167
α-Adrenergic system and drinking behavior 182, 183
β-Adrenergic system
  agonists and respiratory system 360, 361
  and drinking behavior 183
Adrenocorticotropic hormone (ACTH)
  bullfrog sympathetic ganglia 70
  EEG effects 62–6
  evoked potentials 66, 67
  hippocampus and posterior thalamus theta activity 65, 66
  multiple unit activity 67, 68
  postsynaptic action 70, 71
  single neuron activity 70, 71
Adriamycin
  biochemical effects 303, 304
  cell kinetics 308, 309
  cytotoxicity and cell division 304–7
    CHO cells and dose 307
    synchronized cells 307, 308
  resistance 309–11
    drug combinations 311, 312
    hyperthermia 312, 313
    overcoming 311–14
    and radiation 313, 314
  response heterogeneity 309–11
  sites of action 304
  therapy comparisons 314
  tumor growth 308, 309
Adverse drug reactions, antiandrogens 394
Airways
  autonomic mediators 359
  functional anatomy 355–7
  function regulation 359, 360
  pharmacological muscle control 361
  particle deposition 357
Alkylating agents
  cell cycle effects 154–60
    in vitro 154–6
    in vivo 156, 157
  cell cycle phase specificity 150
  cell membranes 154
    transport 149–52
  chromatin 153
  detoxification 149
  DNA interactions 152
  DNA repair deficient cells 158
  future research 157–60
  lipid peroxidation 153
  mechanism of action 147–9
  RNA protein interactions 152
  site of attack 149
γ-Aminobutyric acid (GABA) and drinking behavior 191
Amphetamine
  behavioral profile 4
  drinking behavior 185
Androgen antagonists 367–95
  acne 391, 392
  benign prostatic hypertrophy 393
  contraception 391
  derivatives, 17α acetyl 368–70
  flutamide 374
  metabolism 383–8
  non-steroidal 373–7
  physical properties 368
  precocious puberty 392, 393
  prostate cancer 393, 394
  receptor binding 380–2
  ring modifications, A and D 370–2
  seborrhoea 392
  sexual deviates 394
  side effects 394
  steroidal 368–73
  structures 369–76
  teratology 391
  toxicity 388, 390, 391
Antiarrhythmic activities
  acetylcholine induced 420, 421
  aconite induced 421, 422
  atropine and amiodarone 423
  chemically induced 416–20
    aconite 417, 418, 421, 422
    cardiac glycosides 419
    chloroform 416, 417
    drug effects 417–19
    mechanisms 423, 424
  coronary artery ligation 409
    disadvantages 411, 412
    drug effects 410
    electrocardiogram 411
    types 410
    ventricular 410
  detection and assessment 401–28
  early 408–13
  electrically induced 404–6
    relevance 406
  fibrillation threshold measurement 404–6
  ischaemic fibre study 414
  ischaemia induced 406–14
    conduction delay 413
  late, models 407, 408
  properties 402–4
  reperfusion induced 414–6
  supraventricular arrhythmias 420–3
  ventricular fibrillation 420
Antidiuretic hormone (ADH) and drinking behavior 187, 188
Arachidonic acid metabolism 91–105
  pathways 92
  synthesis 91, 92
Antacoids 359, 360

Behavior, pharmacology of drinking 179–98
  classes 197

Behavioral effects of neuropeptides 1–44
bombesin 37
corticotropic releasing factor 14, 15
LHRH 12, 13
MIF-1 11
neurotensin 15–29
somatostatin 13, 14
substance P 29–37
thyrotropin-releasing hormone 2–11
Bombesin
autonomic effects of central 41, 42
behavioral arousal 37, 38
drinking behavior 189
ingestive behavior 40, 41
rectal and skin temperature 34
thermoregulation 38–40
concentration-response 39

Cancer chemotherapy *see also* individual drugs and treatments
liposome drug carriers 207–27
Canrenone metabolism 388, 389
Capsicain, nociceptive pressure threshold 34
Cardiac cells
cardiac relaxation 139–41
inactivation-dependent 140
load-independent 140
contraction 135, 136
mechanical properties of preparations 133–41
photograph of intact 135
sarcomere distribution 142
sarcomere region behavior 141–3
analysis 143
studies 134
velocity–force relation 136
calcium sensitivity 136, 137
summary 138
time-independence 137–9
velocity of shortening 136
Cardiac conduction and arrhythmias 424, 425
Cardiac membrane preparation 166
Cardiac refractory period and arrhythmias 425, 426
Cell cycle, alkylating agent effects 147–60
Cellular dehydration causes 179
Chlormadinone acetate
metabolites 387
properties 368, 369
Chloroethylnitrosoureas
cell cycle phase specificity 150
structures 148
Cholecystokinin (CCK) and drinking behavior 188
Cholinergic system and drinking behavior 186, 187
Chromolyn sodium 362
Cimetidine
metabolism 388, 390
structure 376
Clonidine and water intake 182
Congestive heart failure
catecholamine-insensitive and H_2 receptor agonists 165–76
haemodynamic measurements 168
isoproterenol effects 168–71
patients studied 167, 168
Controlled drug delivery to respiratory system 355–63
Corticosteroids, respiratory tract effect 361, 362
Corticotropin structure 59
Corticotropin-releasing factor (CRF)
behavioral effects 14, 15
Cyclooxygenase 92
Cyproterone acetate
metabolism 383, 384
properties 368, 369
Cystic fibrosis 435

2-Deoxyglucose and drinking behavior 197
Deoxyribonucleoside triphosphate pool
DNA polymerase inhibitors 295, 296
metabolic map 284
model 281–3
Novikoff hepatoma model 287–90
states 287–90
substrate values 288
purine deoxyribonucleotides 293
pyrimidine deoxyribonucleotides 292, 293
reactions and control mechanisms 283–7
regulation model 279–98
mathematical 285
parameter values 287
rate equations 286
ribonucleoside diphosphate pools 293, 294
ribonucleotide reductase activity 290–2
ribonucleotide reductase inhibitors 294, 295
salvage deoxynucleosides 292, 293
thymidylate synthetase inhibitors 296
transplanted rat hepatoma 291
Diabetes mellitus *see also* insulin secretion
arachidonic acid 91–105
aspirin and blood glucose 102, 103
glucose disappearance and sodium salicylate 104
glucose recognition defect 101, 102
sodium salicylate and insulin secretion 102–4
Diuretic drugs
central effects 194
drinking behavior 193, 194
peripheral effects 193, 194
Dobutamine
cardiac output 171
hemodynamic effects in cardiomyopathy 170, 171
pulmonary wedge pressure 171
Dopamine and drinking behavior 185

Electroencephalogram (EEG), neuronal processes 58, 69
α-Endorphin 326
β-Endorphin
brain enzymes 339, 340
brain synaptic membrane conversion 336–9
brain tissue proteolysis 334–6
cerebrospinal fluid effects 339
cleavage products 81
EEG effects 71–3
fragments 326, 327
half life 341–5
intravenous, pharmacokinetics 342–4
in vitro effects 76–9
multiple unit activity 73
peripheral proteolysis 344, 345
pituitary enzymes 340
proteolytic enzyme effects 334–41
single neuron effect 73–6
structure 59
and species 324–6
γ-Endorphin 326, 327
Enkephalins
EEG effects 71–3

in vitro neuron effects 76–9
multiple unit activity 73
single neuron effects 73–6
Estrogens and drinking behavior 194, 195
Evoked potentials 60, 61

5-Fluorouracil (FUra)
anabolism 108
analogs structures 123, 124
cell death mechanisms 111–13
chemical structure 107
cytotoxicity 115–21
age-response 116, 117
in vivo 118–21
L1210 cell survival 120
murine tumor response 119
proliferative-dependent 117, 118, 120, 121
quantitation 115, 116
DNA effects 109, 110
drug combinations 124, 125
effectiveness modulation 121–5
membrane effects 113
nucleolar effects 113
nucleoside combination 122, 123
resistance 114, 115
RNA effects 110, 111
scheduling 121, 122
sensitivity of cells 114
ternary complex 169
transport effects 108, 109
Flutamide
metabolism and pathways 384, 385
structure 374
2-Formyl-5-hydropyridinethiosemicarbazone
antineoplastic activity 444–6
structure 439

GABA *see* γ-Aminobutyric acid
Gastric ulcers, inducers and neurotensin 27, 28

H_2-receptor agonists
binding studies 167
in congestive heart failure 165–76
Histamine
drinking behavior 191
peripheral and central effects 192
5-Hydroxytryptamine
central effects 186
drinking behavior 186
peripheral effects 186
Hypovolemia causes 179

Insulin and drinking behavior 195, 196
Insulin secretion
A21387 and indomethacin 99
arachidonic acid enhanced 97
cyclooxygenase pathway 94–6
indomethacin stimulation 98
lipoxygenase inhibitors 98
lipoxygenase pathway 96–9
prostaglandins 95
sodium salicylate 97, 100, 101, 103
Interferon action *see also* receptors
actions 236
antiviral action modes 239, 240, 251
reovirus 240
RNA tumor viruses 242–4
simian virus-40 241, 242
vaccinia 241
vesicular stomatitis 240, 241
antiviral state establishment 238
cell surface and receptor binding 236, 238
inducible proteins 238, 239
RNA double-stranded role 235, 236
Interferon treated cell extracts
(2–5) A-phosphodiesterase 248
(2–5) A synthetase 248
double stranded RNA dependent pathways 250, 251
endonuclease 249
pathway 247, 248
protein kinase 246, 247
mRNA methylation inhibition 245
translation inhibition 244, 245
double stranded RNA 246
Isoprenaline induced drinking 184, 185
Isoproterenol
adenylate cyclase activity 168
β-adrenoceptor dysfunction 169
cardiac output 172
hemodynamic effects in cardiomyopathy 170–2
pulmonary wedge pressure 172
receptor binding 169, 170
sweat gland effects 437

Kallikrein-kinin system and drinking behavior 191
Kinetic simulation, multienzyme network inhibition 279–81

Liposomes
antibody coupling 224–7
cancer chemotherapy 207–27
cell interaction mechanisms 212–14
drug delivery problems 215, 216
drugs incorporated 210–12
endothelial barrier 216
glycoprotein bearing 221
hapten bearing 222, 223
instability 217
lymphatic passage 218
physical chemistry 209, 210
physiological disruption 216, 217
protein, covalent coupling 224–7
rationale for uses 214, 215
targeting 218
antibody-mediated 223, 224
compartmental 219
ligand-mediated 220–3
natural 218, 219
physical 219, 220
toxicity and drugs 217
types 208, 209
β-Lipotropin
basic amino acid cleavage 328–30
brain enzyme proteolysis 331
cathepsin B effects 333, 334
cathepsin D effects 329, 331–3
chymotryptic effects 329
derived peptides 323
half-life 341–5
intravenous, pharmacokinetics 342–4
peripheral proteolysis 344, 345
plasmin effects 333
proteolytic enzyme effects 327–34

structure 59
and forms 322–7
tonin effects 333
trypsin effects 333
γ-Lipotropin structure 59, 323, 324
Lipoxygenase 92
Lithium and drinking behavior 196, 197
Luteinizing hormone-releasing hormone (LHRH)
electromagnetic motility score 23
sexual behavior 12, 13

Melanocyte stimulating hormone (MSH)
α, structure 59
β, structure 59, 324
EEG effects 62–6
evoked potentials 66, 67
γ, structure 59
multiple unit activity 67, 68
single neuron effects 68
Melanocyte stimulating hormone release inhibiting factor (MIF-1)
drug-dependent effects 12
drug interactions 11
Metenkephalin structure 59
Methacholine
sweat gland effects 436
sweat rate 436, 437
Mineralocorticoids and drinking behavior 195
Mitral valve stenosis and drugs stimulating adenylate cyclase 174
Multiple unit activity 61

Neuronal processes
microelectrophysiological measurements 61, 62
study techniques 58, 60, 61
Neuropeptides, roles 43, 44
Neurotensin
amphetamine response 21
caudate nucleus 22
nucleus accumbens 21
antinociceptive 24–7
and TRH effect 26
behavioral effects 15–29
centrally active depressant interaction 15, 16
conditioned avoidance 20
dopamine system interactions 19–25
drinking behavior 189
electromagnetic motility scores 23
hot plate latency 27
gastric acid secretion 27, 28
gastric ulcers 27, 28
indomethacin effect 28
motor behavior and ventral tegmental 24
rectal temperature of rats and age 17
thermoregulation 16–19, 25
Nitrogen mustards
cell cycle phase specificity 150
structures 148
Noradrenaline and water intake 182, 183

Opiates
urine output 190
water intake 189, 190
Oxytocin and drinking behavior 195

Pancreatic islet, A 21387 and indomethacin effects 99
Parathyroid hormones and drinking behavior 196
Physaelamin and drinking behavior 188
Prolactin and drinking behavior 195
Pro-opiomelanocortin
derived peptides electrophysiological effects 57–82
primary structure 59
structural organization 322
Prostaglandins
cell binding 92
dipsogenic stimuli 192, 193
drinking behavior 192, 193
mechanism of action 92–4
Prostaglandin E
antilipolytic effect 94
insulin effects 95

Receptor, androgen
antiandrogen binding 380–2
charge 382
processing 382, 383
purification 377–9
size 382
steroid binding specificity 279, 280
Receptors, interferon
binding characteristics 259–63
Dandi cell 262
labeling 260
biological response mechanism 266, 273, 274
down regulation 271, 272
endocytosis 267, 268
genetic loci 266
internalization 268–70
ultrastructure 270, 271
monoclonal antibody binding 265
multiple 263, 264
physical characteristics 263
purification 263
surface orientation 264–6
transport of bound 266, 267
Renin–angiotensin system
cascade 180
converting enzyme inhibition 181, 182
drinking behavior 179–82
inhibitors 181
receptor inhibition 182
Respiratory system
aerosol pharmacokinetics 357, 358
aerosol therapy factors 363
controlled drug delivery 355–63
drug action 360–3
drug efflux 358
drug pulmonary metabolism 359
Ribonucleotide reductase
features 439
inhibitors 439–46
antineoplastic activity 444–6
structural requirements 440, 441
mechanism of action 441–4

Somatostatin, behavioral effects 13, 14
Spironolactone
metabolism 388, 389
structure 370
Substance P
behavioral effects 29–37
cardiovascular effects 37
CNS neurotransmitters 36

drinking behavior 188
ingestion behavior 36, 37
learning 30–3
locomotor activity 33
nociception 33–5
post-trial, alcove avoidance 32
post-trial and step-down avoidance 30–2
Sweat glands
cholinergic sensitivity 436
drug effects and age 435–7

Thiosemicarbazones
antineoplastic activity 444–6
ribonucleotide reductase inhibition 439–46
Thyroid hormones and drinking behavior 196
Thyrotropin-releasing hormone (TRH)
analeptic effect 5–7
autonomic effect 10, 11
behavioral profile 4
DOPAC/DA ratio 4
electromagnetic motility score 3
locomotion and arousal 2–5
neurotensin-induced antinociception 26
pentobarbital response 5
shaking behavior 9, 10
state dependent actions 7, 8
thermoregulation 8, 9
TSAA 291, metabolism 385, 386